Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EUS Celiac Block in Chronic Pancreatitis
NCT01318590Phase 3Terminated
- Sponsor
- Centre hospitalier de l’Université de Montréal
- Start
- Nov 2011
- Primary completion
- Jun 2019
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of bupivacaine hydrochloride 0.75% injection and triamcinolone in chronic pancreatitis (CP) (2 arms), sponsored by Centre hospitalier de l’Université de Montréal. Primary endpoint: Pain reduction on Likert scale. Started Nov 2011; status: terminated.
02
Drugs
bupivacaine hydrochloride 0.75% injectiontriamcinolone
03
Conditions
chronic pancreatitis (CP)
Beyond the preview
Go deeper on NCT01318590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01318590.